OR WAIT null SECS
MilliporeSigma announced the opening of its first end-to-end biodevelopment center in the Asia Pacific (APAC) region.
On Sept. 21, 2017, MilliporeSigma, the life-science subsidiary of Merck KGaA, announced the opening of its first end-to-end biodevelopment center in the Asia Pacific (APAC) region. The center, located in Shanghai, China, will provide a range of process development capabilities and services, including upstream and downstream process development, non-GMP clinical production, and cell line development.
The facility will also provide an integrated suite of services for biopharmaceutical companies across APAC to facilitate clinical drug development from molecule to commercial production. Following the opening of the Martillac, France site in 2012, the development of the Shanghai center is part of company efforts announced in January 2017 to expand its global reach, with a center in Burlington, MA still in development.